News about Quality / GMP

Supriya Lifescience Secures WHO GMP Certification for Ambernath Facility

Supriya Lifescience Secures WHO GMP Certification for Ambernath Facility

The WHO certification for Supriya Lifescience paves way for commercial formulations’ production with INR 500 crore revenue potential.

Quality / GMP | 04/10/2025 | By Dineshwori 377

French Court Orders Sanofi to Pay Euro 177 Million for Anti-Competitive Practices Over Plavix

French Court Orders Sanofi to Pay Euro 177 Million for Anti-Competitive Practices Over Plavix

A French court has ordered Sanofi to pay 177 million euro after ruling that the company engaged in anti-competitive behaviour to protect sales of its blockbuster blood thinner, Plavix. The decision follows a long-running investigation into allegations that Sanofi misled doctors and pharmacists about the safety of generic versions of the drug.

Quality / GMP | 25/09/2025 | By Darshana 507

ICMR and CDSCO Release First Set of 39 Standard IVD Evaluation Protocols

ICMR and CDSCO Release First Set of 39 Standard IVD Evaluation Protocols

Standard In-Vitro Diagnostic (IVD) Evaluation Protocols, jointly developed by ICMR and CDSCO, include protocols for performance evaluation of IVD kits used for detecting tuberculosis, malaria, dengue, chikungunya, Zika virus, typhoid fever, various respiratory viruses, Chandipura virus, and Nipah virus.

Quality / GMP | 19/09/2025 | By Dineshwori 377

India Now Among Top Global Reporters of Drug Adverse Events, Says DCGI

India Now Among Top Global Reporters of Drug Adverse Events, Says DCGI

India has emerged as one of the top global contributors in reporting adverse drug events, according to Dr Rajeev Raghuvanshi, Drugs Controller General of India (DCGI). He made the remarks during the inauguration of the 5th National Pharmacovigilance Week in New Delhi.

Quality / GMP | 18/09/2025 | By Darshana 147

NATCO Pharma's Kothur Facility Receives FDA EIR with VAI Classification

NATCO Pharma's Kothur Facility Receives FDA EIR with VAI Classification

The US Food and Drug Administration (FDA) has completed an inspection at NATCO Pharma’s Pharma division located in Kothur, Hyderabad, India.

Quality / GMP | 18/09/2025 | By Dineshwori 638

AVITA Medical Receives CE Mark for RECELL GO

AVITA Medical Receives CE Mark for RECELL GO

With the CE Mark secured, AVITA Medical will begin commercialisation of RECELL GO in select European countries, including Germany, Italy and the United Kingdom, in collaboration with burn centres and clinical partners.

Quality / GMP | 17/09/2025 | By Dineshwori 141

Alembic Pharmaceuticals Receives US FDA Compliance Report for Panelav API Facilities

Alembic Pharmaceuticals Receives US FDA Compliance Report for Panelav API Facilities

Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for the inspection conducted at its API-I and API-II facilities in Panelav, Gujarat.

Quality / GMP | 15/09/2025 | By Dineshwori 595

Dr. Reddy's Biologics Facility in Hyderabad Receives USFDA Form 483 with Five Observations

Dr. Reddy's Biologics Facility in Hyderabad Receives USFDA Form 483 with Five Observations

The USFDA has completed a Pre-Approval Inspection (PAI) at Dr. Reddy's biologics manufacturing facility in Bachupally, Hyderabad, with five observations.

Quality / GMP | 13/09/2025 | By Dineshwori 589

Cohance's Jaggaiahpet API Plant Clears USFDA Inspection with Zero 483 Observations

Cohance's Jaggaiahpet API Plant Clears USFDA Inspection with Zero 483 Observations

The United States Food and Drug Administration (USFDA) has completed a general current Good Manufacturing Practices (cGMP) audit at Cohance Lifesciences' API manufacturing facility (API Unit1) located at Jaggaiahpet, Andhra Pradesh, with zero Form 483 observations.

Quality / GMP | 12/09/2025 | By Dineshwori 447

Sun Pharma Halol Facility Classified OAI by US FDA, Shipments Restricted

Sun Pharma Halol Facility Classified OAI by US FDA, Shipments Restricted

The US Food and Drug Administration (FDA) has classified Sun Pharma's Halol facility as “Official Action Indicated” (OAI) following an inspection conducted between June 2 and June 13, 2025.

Quality / GMP | 10/09/2025 | By Dineshwori 748

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members